Halozyme Therapeutics HALO Stock options excluded as their inclusion would be anti-dilutive (in shares)
Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's stock options excluded as their inclusion would be anti-dilutive (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's stock options excluded as their inclusion would be anti-dilutive (in shares)?
- Halozyme Therapeutics (HALO) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 27.9M in Q1 2026.
- How has Halozyme Therapeutics's stock options excluded as their inclusion would be anti-dilutive (in shares) changed year-over-year?
- Halozyme Therapeutics's stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 15.8% year-over-year, from 24.1M to 27.9M.